Anadol R, et al. - Researchers compared long-term outcomes in diabetic patients and non-diabetics who received at least one Absorb bioresorbable scaffold (BRS) in the time of May 2012 to December 2014. Using quantitative coronary angiography (QCA) in this single-center registry, 657 patients including 138 patients (21%, mean age 65 ± 11, 78% male) with diabetes were assessed for endpoints including death, cardiovascular death (CV death), myocardial infarction (MI) and target vessel MI (TVMI), target lesion revascularization (TLR), target vessel revascularization (TVR), clinically relevant scaffold restenosis (ScR) and scaffold thrombosis (ScT). As for metal stents, diabetes was found to be related to an increased incidence of scaffold restenosis and related outcomes beyond one year after implantation. Use of an optimal implantation technique led to reset of this negative impact of diabetes.